Drug Trial News

RSS

FDA allows IND application for ImmunoCellular’s ICT-140 to treat ovarian cancer

ImmunoCellular Therapeutics, Ltd. announced that the US Food and Drug Administration (FDA) has allowed the investigational new drug (IND) application for ICT-140, paving the way for conducting a clinical trial.

30 Jan 2013

Botulinum toxin A does not promote weight loss in obese patients

Despite conflicting data in support of the practice, some overweight Americans looking for an easy fix have turned to gastric botox injections to help them lose weight. This month in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association, researchers from the Mayo Clinic publish a definitive study finding that Botox doesn't promote weight loss.

29 Jan 2013

Bone Medical announces initial findings from BN006 proof of concept RA study

Bone Medical Ltd, a biopharmaceutical company focused on the development of new medicines for musculoskeletal diseases, today announced initial findings from a proof of concept study of BN006, a treatment that it is developing for Rheumatoid Arthritis (RA) based on its Mozaic™ peptide discovery technology.

29 Jan 2013

Janssen, Medivir and Idenix partner for clinical development of HCV combination therapy

Medivir AB today announced a non-exclusive collaboration between Janssen Pharmaceuticals Inc. (Janssen) and Idenix Pharmaceuticals for the clinical development of an all-oral (interferon-free) direct-acting antiviral (DAA) hepatitis C (HCV) combination therapy.

29 Jan 2013

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced the initiation of a global phase III clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed CD30-positive mature T-cell lymphoma (MTCL) patients, including patients with systemic anaplastic large cell lymphoma (sALCL) and other types of peripheral T-cell lymphomas.

28 Jan 2013

Positive top-line results from Biogen Idec’s peginterferon beta-1a Phase 3 trial on RRMS

Today Biogen Idec released the primary efficacy analysis and safety data from its Phase 3 pivotal clinical trial, ADVANCE.

28 Jan 2013

Gilead commences first of two tenofovir alafenamide Phase 3 trials in HIV

Gilead Sciences, Inc. today announced the initiation of the first of two Phase 3 clinical trials (Study 104) evaluating a single tablet regimen containing tenofovir alafenamide (TAF) for the treatment of HIV-1 infection in treatment-naïve adults.

28 Jan 2013

Results from Amgen’s Neulasta plus bevacizumab Phase 3 trial on colorectal cancer

Amgen announced today results from Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES), a Phase 3 trial which evaluated Neulasta (pegfilgrastim) in 845 patients receiving FOLFOX or FOLFIRI and bevacizumab for the first-line treatment of locally-advanced or metastatic colorectal cancer.

28 Jan 2013

Interim results from Seattle Genetics’ ASG-5ME phase I trial on metastatic PDA

Seattle Genetics, Inc. today presented interim results from a phase I clinical trial evaluating ASG-5ME for the treatment of metastatic pancreatic ductal adenocarcinoma (PDA) at the American Society of Clinical Oncology (ASCO) 2013 Gastrointestinal Cancers Symposium being held January 24-26, 2013 in San Francisco, CA.

28 Jan 2013

Researchers study innovative stem cell drug for treating localized cartilage damage

Rush University Medical Center is conducting the nation's first clinical study of an innovative stem cell drug, Cartistem, to repair knee cartilage damaged by aging, trauma or degenerative diseases such as osteoarthritis.

25 Jan 2013

New hope for lupus patients

A clinical trial with 149 patients suffering from the very disabling autoimmune disease systemic lupus erythematosus, has shown the effectiveness of a synthetic peptide developed by a team of researchers led by CNRS biologist Slyviane Muller at the Institut de Biologie Moleculaire (IBMC) in Strasbourg, France.

25 Jan 2013

Neuromuscular blockade (NMB) reversal

General anesthesia is made up of three components: hypnotic medicines, to induce sleep; analgesics, or medicines to inhibit pain; and NMB agents that induce muscle relaxation. Anesthesiology professionals use NMB to relax a patient’s muscles and prevent involuntary movement that could impact surgery.

24 Jan 2013

Clinical trial to evaluate cyclodextrin against Niemann-Pick disease type C1

A clinical trial to evaluate a drug candidate called cyclodextrin as a possible treatment for Niemann-Pick disease type C1 (NPC), a rare and fatal genetic disease, will start today, researchers announced.

24 Jan 2013

Tofacitinib improves disease activity and inhibits progression of joint damage in RA patients

A Phase 3 clinical trial demonstrates that tofacitinib improves disease activity and inhibits progression of joint damage in rheumatoid arthritis (RA) patients who did not respond to methotrexate (MTX).

24 Jan 2013

Positive results from BioInvent's BI-505 phase I study on multiple myeloma

BioInvent International announced today the first results from the BI-505 phase I study in patients with multiple myeloma.

24 Jan 2013

Pomalidomide safe, effective and extends overall survival for patients with multiple myeloma

Researchers at Moffitt Cancer Center and colleagues have investigated the safety, efficacy and the maximum tolerated dose of pomalidomide for patients with multiple myeloma who have disease relapsed after treatments with other drugs, such as bortezomib and lenalidomide.

24 Jan 2013

NIH's candidate vaccine safe in treating dengue

A candidate dengue vaccine developed by scientists at the National Institutes of Health (NIH) has been found to be safe and to stimulate a strong immune response in most vaccine recipients, according to results from an early-stage clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH. The trial results were published online on January 17 in the Journal of Infectious Diseases.

23 Jan 2013

Update on microdosing

One of yesterday's most promising new tools for speeding the development of new medicines - "microdosing" - has found niches in that process today, and they include uses unanticipated a decade ago.

23 Jan 2013

Article analyzes role of nutrition in mood swings

In this study, preliminary data yields conflicting but mainly positive evidence for the use of n-3 fatty acids and chromium in the treatment of bipolar depression. Limited evidence found that inositol may be helpful for bipolar depression, but larger sample sizes are needed. Preliminary randomized, controlled trials suggest that choline, magnesium, folate and tryptophan may be beneficial for reducing symptoms of mania.

23 Jan 2013

Taking antiepileptic drug valproate during pregnancy affects the IQ of children

Research published in The Lancet Neurology shows that taking the antiepileptic drug valproate during pregnancy affects the IQ of children up to the age of six.

23 Jan 2013

Drug Trial News

FDA allows IND application for ImmunoCellular’s ICT-140 to treat ovarian cancer

Botulinum toxin A does not promote weight loss in obese patients

Bone Medical announces initial findings from BN006 proof of concept RA study

Janssen, Medivir and Idenix partner for clinical development of HCV combination therapy

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Positive top-line results from Biogen Idec’s peginterferon beta-1a Phase 3 trial on RRMS

Gilead commences first of two tenofovir alafenamide Phase 3 trials in HIV

Results from Amgen’s Neulasta plus bevacizumab Phase 3 trial on colorectal cancer

Interim results from Seattle Genetics’ ASG-5ME phase I trial on metastatic PDA

Researchers study innovative stem cell drug for treating localized cartilage damage

New hope for lupus patients

Neuromuscular blockade (NMB) reversal

Clinical trial to evaluate cyclodextrin against Niemann-Pick disease type C1

Tofacitinib improves disease activity and inhibits progression of joint damage in RA patients

Positive results from BioInvent's BI-505 phase I study on multiple myeloma

Pomalidomide safe, effective and extends overall survival for patients with multiple myeloma

NIH's candidate vaccine safe in treating dengue

Update on microdosing

Article analyzes role of nutrition in mood swings

Taking antiepileptic drug valproate during pregnancy affects the IQ of children

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Latest News